tert-butyl 3-((1-methyl-4-oxo-3-((2-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)carbamoyl)-1,4-dihydroquinolin-7-yl)amino)propanoate | 1351945-45-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 3-((1-methyl-4-oxo-3-((2-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)carbamoyl)-1,4-dihydroquinolin-7-yl)amino)propanoate
• CAS: 1351945-45-3
• 化学式: C₃₁H₃₀F₃N₃O₄
• 分子量: 565.592
• InChiKey: JIXSDVUGCKJOLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.62
• 重原子数：
  41.0
• 可旋转键数：
  7.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  89.43
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-((1-methyl-4-oxo-3-((2-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)carbamoyl)-1,4-dihydroquinolin-7-yl)amino)propanoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以27%的产率得到3-((1-methyl-4-oxo-3-((2-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)carbamoyl)-1,4-dihydroquinolin-7-yl)amino)propanoic acid
  参考文献：
  名称：

  Optimization of a Potent, Orally Active S1P₁ Agonist Containing a Quinolinone Core

  摘要：

  The optimization of a series of SIP, agonists with limited activity against S1P(3) is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.

  DOI：

  10.1021/ml200252b
• 作为产物：
  描述：

  ethyl 7-bromo-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 4a,9a-dihydro-9,9-dimethyl-4,5-bis(diphenylphosphino)-xanthene 、 lithium hydroxide monohydrate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 sodium t-butanolate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 38.0h， 生成 tert-butyl 3-((1-methyl-4-oxo-3-((2-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)carbamoyl)-1,4-dihydroquinolin-7-yl)amino)propanoate
  参考文献：
  名称：

  Optimization of a Potent, Orally Active S1P₁ Agonist Containing a Quinolinone Core

  摘要：

  The optimization of a series of SIP, agonists with limited activity against S1P(3) is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.

  DOI：

  10.1021/ml200252b